PCOS is now PMOS: what the new name changes, and what it doesn’t
The old name described cysts. The new one describes the metabolism. For anyone choosing care, that shift is the whole point.
The short answer: on 12 May 2026, a coalition of more than fifty patient and professional organisations, including the Endocrine Society and the American Society for Reproductive Medicine, renamed polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS). The condition is the same, and your diagnosis still stands. The name changed because PCOS is a whole-body hormonal and metabolic condition, and the “cysts” in the old name were never the cause. Both names will be used during a three-year transition.
Why the old name never fit
“Polycystic ovary syndrome” told patients and clinicians to look at the ovaries, and specifically for cysts. But the small follicles seen on an ultrasound are not true cysts, are not what drives the condition, and are not present in everyone who has it. Meanwhile the parts of the condition that shape daily life, and long-term health, went unnamed: insulin resistance, raised androgens, irregular cycles, and a higher risk of type 2 diabetes and heart disease.
A name steers attention. For decades, this one steered it toward a scan and away from a blood test.
What the new name says
Read it piece by piece. Polyendocrine: several hormone systems are involved, not one organ. Metabolic: insulin and metabolism are central, not a side note. Ovarian: the ovaries are still part of the picture, just not the whole of it. The rename was agreed by a coalition of more than fifty organisations and announced on 12 May 2026, with a transition of about three years during which both names are used.
That is why this site writes “PMOS (PCOS).” The new name is the accurate one; the old one is still how most people search.
What stays exactly the same
- Your diagnosis. If you were diagnosed with PCOS, you have PMOS. Nothing needs to be redone.
- How it is diagnosed. The rename did not change the diagnostic criteria.
- Your treatment plan. Nothing about the rename requires you to change a medication. Any change is a conversation with your own clinician.
The condition did not change in May. The label finally caught up with it.
What it should change about the care you get
This is where the rename matters for anyone choosing a GLP-1 provider. If the condition is named for its metabolism, care that looks only at the scale is looking at the wrong thing. In practice, PMOS-aware care means:
- Labs that check fasting insulin, A1c and androgens, not weight alone. We list the five worth asking for.
- Clinicians who understand androgen symptoms and irregular cycles without needing them explained.
- A plan that treats insulin resistance as the point of the work, which is the thread we follow in why PMOS is an insulin story.
Those are the first three of Lantana’s Root Eight standards. We wrote them before the rename, and the new name describes the same idea.
What it does not change about GLP-1s
A new name does not make any medication a PMOS treatment. GLP-1 medications, including tirzepatide, are not FDA-approved to treat PCOS (PMOS). Where cycles or androgen symptoms improve, that follows from weight loss and better insulin sensitivity rather than the medication treating the syndrome. Compounded tirzepatide is not FDA-approved and is not reviewed by the FDA for safety or efficacy.